CervoMed Inc.CRVO

CervoMed Inc. (CRVO) focuses on neurology, particularly in the treatment of Dementia with Lewy Bodies (DLB). Globally, DLB prevalence is in the millions, and there are no approved treatments in the United States or the European Union. The company's lead investigational drug, neflamapimod, has been studied in multiple clinical trials for DLB.

The AscenD-LB Phase 2a trial enrolled 91 participants, while the RewinD-LB Phase 2b trial enrolled 159 patients. In the RewinD-LB trial, neflamapimod treatment resulted in a CDR-SB change from baseline of 0.17, compared to an increase of 0.95 for placebo. The RewinD-LB Phase 2b clinical trial also showed a right BF volume change from baseline of +10.9 mm³ and a right BF volume percentage change of 3.5%. Conversely, another finding from the RewinD-LB Phase 2b clinical trial reported a right BF volume change from baseline of -13.3 mm³ and a right BF volume percentage change of -4.2%. The planned Phase 3 trial for neflamapimod will use a dose of 50 mg TID. The company anticipates FDA alignment on the registration path in the US in November 2025.